Deccan Healthcar

Why is Deccan Health Care Ltd falling/rising?

As of 16-Aug, Deccan Health Care Ltd's stock price is at 12.81, reflecting a decline of 4.97%. The stock has significantly underperformed compared to the Sensex over various time frames, indicating a bearish trend despite increased investor participation.

As of 16-Aug, Deccan Health Care Ltd's stock price is falling, currently at 12.81, which reflects a change of -0.67 or -4.97%. The stock has underperformed its sector by 4.11% today and has experienced a trend reversal, having fallen after two consecutive days of gains. Over the past week, the stock has declined by 1.46%, while the benchmark Sensex has only decreased by 0.62%. <BR><BR>Looking at the longer-term performance, the stock has shown significant declines, with a year-to-date drop of 13.50% compared to an 8.46% decline in the Sensex. Over the past year, Deccan Health Care Ltd has decreased by 34.27%, while the Sensex has only fallen by 3.21%. The three-year performance shows an even steeper decline of 47.41% against a 19.28% increase in the Sensex, and over five years, the stock has fallen by 51.66% while the Sensex has risen by 40.72%.<BR><BR>Despite a rise in investor participation, with delivery volume increasing by 77.95% on August 13 compared to the five-day average, the stock remains lower than several key moving averages, specifically the 20-day, 50-day, and 200-day moving averages, indicating a bearish trend. Overall, these factors contribute to the current decline in Deccan Health Care Ltd's stock price.

Should I buy, sell or hold Deccan Health Care Ltd?

Which are the latest news on Deccan Healthcar?

Who are in the management team of Deccan Healthcar?

The management team of Deccan Healthcare includes Minto Gupta (Chairman & Managing Director), Meenakshi Gupta (Director), Ruchi Khattar (Independent Director), Kandlakunta Samhitha (Independent Director), and Ravi Ram Prasad (Director).

The management team of Deccan Healthcare includes the following individuals:<BR><BR>1. **Minto Gupta** - Chairman & Managing Director<BR>2. **Meenakshi Gupta** - Director<BR>3. **Ruchi Khattar** - Independent Director<BR>4. **Kandlakunta Samhitha** - Independent Director<BR>5. **Ravi Ram Prasad** - Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Deccan Healthcar do?

Deccan Health Care Ltd is a micro-cap company specializing in the development, manufacturing, and marketing of healthcare products, including nutraceuticals, cosmeceuticals, and ayurveda products. As of March 2026, it reported net sales of 21 Cr and a market cap of INR 32 Cr.

Overview:<BR>Deccan Health Care Ltd is a micro-cap company in the healthcare services industry, focused on developing, manufacturing, and marketing a diverse range of healthcare products including nutraceutical, cosmeceutical, and ayurveda products.<BR><BR>History:<BR>Incorporated on August 31, 2017, Deccan Health Care Ltd has an operating history of over two decades in the healthcare sector. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 21 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 32 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 13.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.02 <BR>Return on Equity: 2.25% <BR>Price to Book: 0.29 <BR><BR>Contact Details:<BR>Address: 247 2nd Flr Dwarakapuri Colony, Punjagutta Hyderabad Telangana : 500082 <BR>Tel: 91-040-40144508 <BR>Email: investors@deccanhealthcare.co.in <BR>Website: http://www.deccanhealthcare.co.in

Who are the peers of the Deccan Healthcar?

Deccan Healthcar's peers include KMS Medisurgi, Amkay Products, N G Industries, Bandaram Pharma, GKB Ophthalmics, Centenial Surgic, Tejnaksh Health, Chennai Meena, and Sunrest Lifescie. Management risk varies from excellent to below average among peers, with Deccan Healthcar showing below average growth and a 1-year return of -30.23%.

Peers: The peers of Deccan Healthcar are KMS Medisurgi, Amkay Products, N G Industries, Bandaram Pharma, GKB Ophthalmics, Centenial Surgic, Tejnaksh Health., Chennai Meena, Sunrest Lifescie.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amkay Products, N G Industries, and Sunrest Lifescie, while Average management risk is found at KMS Medisurgi. Below Average management risk is present at Bandaram Pharma, Deccan Healthcar, GKB Ophthalmics, Centenial Surgic, Tejnaksh Health., and the rest. Growth is Excellent at Sunrest Lifescie, Good at Amkay Products, N G Industries, Deccan Healthcar, GKB Ophthalmics, and Bandaram Pharma, while Below Average growth is noted at KMS Medisurgi, Centenial Surgic, Tejnaksh Health., and the rest. Capital Structure is Good at Amkay Products, N G Industries, Deccan Healthcar, GKB Ophthalmics, and Tejnaksh Health., while Average is seen at Centenial Surgic and Below Average at Bandaram Pharma.<BR><BR>Return Snapshot: GKB Ophthalmics has the highest 1-year return at -13.34%, while Bandaram Pharma has the lowest at -51.19%. Deccan Healthcar's 1-year return is -30.23%, which is better than Bandaram Pharma but worse than GKB Ophthalmics. Additionally, KMS Medisurgi, Amkay Products, N G Industries, Bandaram Pharma, Centenial Surgic, Tejnaksh Health., and the rest have negative six-month returns.

How big is Deccan Healthcar?

As of 14th August, Deccan Health Care Ltd has a market capitalization of 33.16 Cr and reported net sales of 81.91 Cr and net profit of 2.48 Cr over the latest four quarters.

As of 14th August, <BR><BR>Market Cap: Deccan Health Care Ltd has a market capitalization of 33.16 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 81.91 Cr, while the sum of Net Profit for the same period is 2.48 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 106.39 Cr and Total Assets valued at 124.93 Cr.

Are Deccan Health Care Ltd latest results good or bad?

Deccan Health Care Ltd's latest results are largely negative, showing a 67% drop in net profit despite a 20.64% revenue increase. The significant decline in operating and PAT margins raises concerns about the company's operational efficiency and profitability sustainability.

Deccan Health Care Ltd's latest results present a mixed picture, but overall, they lean towards the negative side. In Q4 FY26, the company reported a net profit of ₹0.33 crore, which is a significant drop of 67% compared to the previous quarter. However, there is a positive year-on-year comparison, with a 175% increase from the same quarter last year.<BR><BR>On the revenue front, Deccan Health Care saw a robust growth of 20.64% quarter-on-quarter, reaching ₹20.98 crore, and a slight increase of 1.11% year-on-year. Despite this revenue growth, the company's operating margin fell sharply from 9.95% in Q3 FY26 to just 4.24% in Q4 FY26, indicating significant operational challenges. The PAT margin also decreased from 5.75% to 1.57%, highlighting pressure on profitability.<BR><BR>Overall, while the revenue growth is encouraging, the drastic decline in net profit and margins suggests that the company is facing serious operational inefficiencies and challenges in maintaining profitability. This disconnect between revenue growth and profit performance raises concerns about the sustainability of its business model. Given these factors, the results can be viewed as unfavorable, particularly for investors focused on profitability and return on equity.

When is the next results date for Deccan Health Care Ltd?

The next results date for Deccan Health Care Ltd is 13 February 2026.

The next results date for Deccan Health Care Ltd is scheduled for 13 February 2026.

How has been the historical performance of Deccan Healthcar?

Deccan Healthcar has experienced fluctuating financial performance, with net sales increasing from INR 33.17 crore in March 2022 to INR 75.06 crore in March 2025, but operating profit and cash flow remain negative, indicating ongoing operational challenges. Total assets and liabilities have both risen to INR 124.93 crore by March 2025.

Answer:<BR>The historical performance of Deccan Healthcar shows a fluctuating trend in key financial metrics over the past several years.<BR><BR>Breakdown:<BR>Deccan Healthcar's net sales have shown a consistent increase from INR 33.17 crore in March 2022 to INR 75.06 crore in March 2025. However, the total operating income has mirrored this growth, reaching INR 75.06 crore in March 2025. The raw material cost has also risen significantly, from INR 3.98 crore in March 2022 to INR 40.89 crore in March 2025, indicating increased operational expenses. The total expenditure, excluding depreciation, has escalated from INR 27.83 crore in March 2022 to INR 71.91 crore in March 2025. Consequently, the operating profit (PBDIT) has seen a decline from INR 5.34 crore in March 2022 to INR 3.16 crore in March 2025. Profit before tax has also decreased from INR 0.54 crore in March 2022 to INR 1.63 crore in March 2025, while profit after tax has fluctuated, reaching INR 1.16 crore in March 2025, down from INR 0.32 crore in March 2022. The company's total assets have increased from INR 90.63 crore in March 2022 to INR 124.93 crore in March 2025, alongside total liabilities rising from INR 90.63 crore to INR 124.93 crore in the same period. Cash flow from operating activities has remained negative, with a cash flow of -6.00 crore in March 2025, reflecting ongoing challenges in cash generation despite a net cash inflow of 0.00 crore in the same year.

Is Deccan Healthcar overvalued or undervalued?

As of October 6, 2025, Deccan Healthcare's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 42.12, an EV to EBITDA of 13.43, and a low EV to Book Value of 0.41, especially when compared to peers like Sun Pharma and Cipla.

As of 6 October 2025, the valuation grade for Deccan Healthcar has moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued, particularly when considering its current PE ratio of 42.12, an EV to EBITDA of 13.43, and a notably low EV to Book Value of 0.41. These ratios suggest that the market may not fully recognize the company's potential relative to its earnings and assets.<BR><BR>In comparison to its peers, Deccan Healthcar's valuation stands out; for instance, Sun Pharma has a PE ratio of 34.56 but is considered expensive, while Cipla, also rated attractive, has a significantly lower PE of 22.72. The PEG ratio of Deccan Healthcar is 0.00, which further emphasizes its undervaluation compared to peers like Divi's Lab, which is categorized as very expensive with a PEG of 1.78. Additionally, the company's stock has underperformed against the Sensex over various periods, which may contribute to its current attractive valuation status.

Who are the top shareholders of the Deccan Healthcar?

The top shareholders of Deccan Healthcar include Minto Purshotam Gupta with 14.46%, Focal Ventures Private Limited at 9.69%, and individual investors holding a combined 47.83%. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Deccan Healthcar include Minto Purshotam Gupta, who holds the largest stake at 14.46%. Following him, Focal Ventures Private Limited is the highest public shareholder with a 9.69% ownership. Additionally, individual investors collectively hold 47.83% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Deccan Healthcar?

As of May 15, 2025, Deccan Healthcare's trend is mildly bearish, influenced by daily moving averages, while weekly indicators show mixed signals, suggesting a cautious outlook.

As of 15 May 2025, the technical trend for Deccan Healthcare has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish trend, while the weekly MACD and Bollinger Bands show a mildly bullish signal. The monthly indicators, including MACD and KST, remain bearish, suggesting underlying weakness. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum. Overall, the mixed signals across different time frames reflect a cautious outlook for the stock.

Has Deccan Healthcar declared dividend?

No Dividend History Available